Theravance SVP sells 13,314 shares in open market

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported selling ordinary shares in open-market transactions.

Rhea-AI Filing Summary

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported selling ordinary shares in open-market transactions. On June 15, 2026, she sold a total of 13,314 ordinary shares of Theravance Biopharma in three separate trades.

The reported sale prices were around the mid‑$16 range per share, with individual weighted-average prices of $16.3856, $16.3838 and $16.3902. A footnote explains that these transactions were executed in multiple trades between $16.21 and $16.61 per share, and the prices disclosed reflect the weighted-average sale prices across those trades.

Insider Trade Summary 10b5-1

Net Seller: 13,314 shares

Net Sell 3 txns

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Sold 13,314 shs ($218K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,329	$16.3902	$55K
Sale	Ordinary Shares	3,328	$16.3838	$55K
Sale	Ordinary Shares	6,657	$16.3856	$109K

Holdings After Transaction: Ordinary Shares — 232,457 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares sold: 13,314 shares Sale price tranche 1: $16.3856 per share Sale price tranche 2: $16.3838 per share +2 more

5 metrics

Total shares sold 13,314 shares Open-market sales on June 15, 2026

Sale price tranche 1 $16.3856 per share Weighted-average price for 6,657-share sale

Sale price tranche 2 $16.3838 per share Weighted-average price for 3,328-share sale

Sale price tranche 3 $16.3902 per share Weighted-average price for 3,329-share sale

Footnote price range $16.21–$16.61 per share Range of execution prices for reported sales

Key Terms

open-market sale, Ordinary Shares, weighted average sale price, Form 4

4 terms

open-market sale financial

"transaction_action: "open-market sale" for each ordinary share transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title: "Ordinary Shares" for all non-derivative transactions"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Form 4 regulatory

"INSIDER FILING DATA (Form 4): structured insider transaction details"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theravance Biopharma (TBPH) report for Rhonda Farnum?

Theravance Biopharma reported that SVP Rhonda Farnum sold 13,314 ordinary shares in open-market transactions. The trades occurred on June 15, 2026, and were disclosed on Form 4 as routine insider sales of existing holdings.

How many Theravance Biopharma (TBPH) shares did Rhonda Farnum sell?

Rhonda Farnum sold a total of 13,314 ordinary shares of Theravance Biopharma. The sale was split into three separate open-market trades, each reported with its own weighted-average sale price around the mid‑$16 range per share.

At what prices were Rhonda Farnum’s Theravance Biopharma (TBPH) shares sold?

The reported weighted-average sale prices were $16.3856, $16.3838 and $16.3902 per share. A footnote notes that the underlying trades were executed in a price range from $16.21 to $16.61 per share on June 15, 2026.

What type of transaction did the Theravance Biopharma (TBPH) Form 4 disclose?

The Form 4 discloses open-market sales of ordinary shares by SVP Rhonda Farnum. All three transactions are coded “S,” indicating sales in the open market or private transactions, and involve non-derivative common equity of Theravance Biopharma.

Did Rhonda Farnum use derivatives in her Theravance Biopharma (TBPH) transaction?

No, the reported transactions involve only non-derivative ordinary shares of Theravance Biopharma. The filing’s derivative section shows no option or warrant exercises, indicating these were straightforward sales of existing share holdings rather than conversions of derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 07:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/15/2026		S		3,329	D	$16.3902(1)	242,442	D
Ordinary Shares	06/15/2026		S		3,328	D	$16.3838(1)	239,114	D
Ordinary Shares	06/15/2026		S		6,657	D	$16.3856(1)	232,457	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025.

	/s/ Brett A. Grimaud, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)